FDA Accepts Biologics License Application for Subcutaneous F

The new administration method, which is co-formulated with rHuPH20, is usable in previous approved nivolumab indications for solid tumors in adult patients.

Related Keywords

United States , American , Bristol Myers Squibb , Gina Fusaro , National Cancer Institute , American Society Of Clinical Oncology , Has Spread , American Society , Clinical Oncology , Drug Administration Accepts Bristol Myers Squibb , Subcutaneous Nivolumab , Results Support Subcutaneous Nivolumab Treatment , Patients With Metastatic , Early Stage Lung Cancer , Surgery Proves , National Cancer ,